Advertisement

Ads Placeholder
Loading...

Inogen, Inc.

INGNNASDAQ
Healthcare
Medical - Devices
$6.21
$-0.06(-0.96%)
U.S. Market opens in 20h 20m

Inogen, Inc. Fundamental Analysis

Inogen, Inc. (INGN) shows moderate financial fundamentals with a PE ratio of -7.42, profit margin of -6.52%, and ROE of -11.56%. The company generates $0.3B in annual revenue with moderate year-over-year growth of 6.35%.

Key Strengths

Cash Position70.85%
PEG Ratio-0.50
Current Ratio3.12

Areas of Concern

ROE-11.56%
Operating Margin-8.66%
We analyze INGN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 17.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
17.8/100

We analyze INGN's fundamental strength across five key dimensions:

Efficiency Score

Weak

INGN struggles to generate sufficient returns from assets.

ROA > 10%
-7.62%

Valuation Score

Excellent

INGN trades at attractive valuation levels.

PE < 25
-7.42
PEG Ratio < 2
-0.50

Growth Score

Excellent

INGN delivers strong and consistent growth momentum.

Revenue Growth > 5%
6.35%
EPS Growth > 10%
65.61%

Financial Health Score

Excellent

INGN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.09
Current Ratio > 1
3.12

Profitability Score

Weak

INGN struggles to sustain strong margins.

ROE > 15%
-1156.36%
Net Margin ≥ 15%
-6.52%
Positive Free Cash Flow
No

Key Financial Metrics

Is INGN Expensive or Cheap?

P/E Ratio

INGN trades at -7.42 times earnings. This suggests potential undervaluation.

-7.42

PEG Ratio

When adjusting for growth, INGN's PEG of -0.50 indicates potential undervaluation.

-0.50

Price to Book

The market values Inogen, Inc. at 0.88 times its book value. This may indicate undervaluation.

0.88

EV/EBITDA

Enterprise value stands at -62.21 times EBITDA. This is generally considered low.

-62.21

How Well Does INGN Make Money?

Net Profit Margin

For every $100 in sales, Inogen, Inc. keeps $-6.52 as profit after all expenses.

-6.52%

Operating Margin

Core operations generate -8.66 in profit for every $100 in revenue, before interest and taxes.

-8.66%

ROE

Management delivers $-11.56 in profit for every $100 of shareholder equity.

-11.56%

ROA

Inogen, Inc. generates $-7.62 in profit for every $100 in assets, demonstrating efficient asset deployment.

-7.62%

Following the Money - Real Cash Generation

Operating Cash Flow

Inogen, Inc. generates limited operating cash flow of $-11.24M, signaling weaker underlying cash strength.

$-11.24M

Free Cash Flow

Inogen, Inc. generates weak or negative free cash flow of $-21.31M, restricting financial flexibility.

$-21.31M

FCF Per Share

Each share generates $-0.78 in free cash annually.

$-0.78

FCF Yield

INGN converts -12.57% of its market value into free cash.

-12.57%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.42

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.50

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.88

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.49

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.09

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.12

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.12

vs 25 benchmark

ROA

Return on assets percentage

-0.08

vs 25 benchmark

ROCE

Return on capital employed

-0.13

vs 25 benchmark

How INGN Stacks Against Its Sector Peers

MetricINGN ValueSector AveragePerformance
P/E Ratio-7.4228.45 Better (Cheaper)
ROE-11.56%763.00% Weak
Net Margin-6.52%-45265.00% (disorted) Weak
Debt/Equity0.090.34 Strong (Low Leverage)
Current Ratio3.122795.60 Strong Liquidity
ROA-7.62%-16588.00% (disorted) Weak

INGN outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Inogen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-14.44%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-258.03%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-86.56%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ